Quarterly ResultMay 14, 2026, 08:52 AM
Curanex Expands Pipeline to Cancer Cachexia; Q1 Net Loss $3.15M
AI Summary
Curanex Pharmaceuticals Inc. announced a strategic expansion of its drug development pipeline to include cancer cachexia, a severe cancer-related wasting syndrome with no approved therapies in the U.S., representing significant unmet medical needs. This move diversifies its product portfolio and strengthens its position as an emerging biotechnology company. For the first quarter ended March 31, 2026, the company reported a net loss of $3.15 million, a substantial increase from $0.14 million in the prior year, primarily driven by a significant ramp-up in research and development expenses to $2.26 million.
Key Highlights
- Expanded drug development pipeline to include cancer cachexia on April 2, 2026.
- Reported Q1 2026 net loss of $3,150,228, compared to $137,583 in Q1 2025.
- Research & Development expenses surged to $2,256,162 in Q1 2026 from $0 in Q1 2025.
- General & administrative expenses increased to $927,197 in Q1 2026 from $137,452 in Q1 2025.
- Net loss per common share was $(0.11) in Q1 2026, compared to $(0.01) in Q1 2025.
- Cash balance stood at $4,018,574 as of March 31, 2026, down from $4,973,134 at Dec 31, 2025.
- No substantial doubt about going concern due to $13.24M net IPO proceeds and $2.07M over-allotment.
- Issued 24,000 common shares for stock-based compensation on March 18, 2026.